GlaxoSmithKline Czech Republic's operating cash flow stood at CZK -78.2 mil in 2017, up 45.1% when compared to the previous year. Historically, between 2003 - 2017, the firm’s operating cash flow reached a high of CZK 192 mil in 2006 and a low of CZK -556 mil in 2003.
GlaxoSmithKline Czech Republic's total investments stood at CZK -1.83 mil and accounted for 0.077% of sales in 2017. This is compared to an average of 0.153% as seen over the last five years.
Cash from financing amounted to CZK -38.0 mil, so the company generated CZK -118 mil net cash in 2017.
At the end of 2017, the company had a net debt of CZK -209 mil, or -2.15x of EBITDA and -13.8% of equity. Net working capital amounted to CZK 1,154 mil, or 39.8% of sales. Cash conversion cycle is negative and reached 155 days days in 2017. This means GlaxoSmithKline Czech Republic generates revenue from customers before it has to pay its suppliers for inventory, among other things.
You can see all the company’s data at GlaxoSmithKline Czech Republic profile, or you can download a report on the company in the report section.
Helgi Library 
